Opening Session

Monday, 7 October | 16:00 – 18:00

Ntando Yola

OS.01 | 16:40 – 16:50
Partnership Towards a Tough Target: Communities are an Essential Ingredient, Not a Cherry on Top

Ntando Yola
NACOSA, South Africa

Biography

Ntando Yola has worked in HIV prevention research at the Desmond Tutu HIV Foundation (DTHF) in Cape Town for the last 8 years. In his role as a Community Engagement Coordinator, has worked closely with various, national and international HIV prevention research networks. His work has involved, developing and implementing community education programmes and involvement of communities in HIV prevention trials. As part of these programs, he has been involved in formation of partnerships with health service providers, and engaging community based organizations to ensure voices of key stakeholders in HIV prevention trials are heard. All of this work has largely taken place in the trial communities of Masiphumelele and Nyanga townships of Cape Town for HIV vaccine, microbicide, and pre-exposure prophylaxis clinical trials. His work is driven by a desire to involve communities in research, hear their voices and see them take ownership as part of achieving an end to the AIDS epidemic.

He is also a 2013 AVAC HIV Prevention Research Fellow, hosted by NACOSA. In his fellowship, Ntando will explore opportunities and develop strategies for broad stakeholder engagement in clinical trials across South Africa (SA). Promoting the Good Participatory Practice (GPP) Guidelines, ensure a systematic involvement of communities and stakeholders in trials. This would happen through a formation of a national forum that will bring together all stakeholders from trial communities, Community Advisory Boards, civil society and advocacy groups. This forum would provide a framework of broad stakeholder engagement, HIV prevention research literacy and inform an agenda that will support research as well as look at advocacy issues within the trial process. One of the key deliverables would be to have the HIV prevention research agenda linked and featured in the HIV/AIDS, STI and TB National Strategic Plan of (NSP) of SA.

Ntando is also involved with the South African AIDS Council (SANAC); Men’s sector Western Cape serving as a Secretary.

 

 
Stanley Plotkin

OS.02 | 16:50 – 17:13
HIV Vaccines in the Context of Vaccine Development in General

Stanley Plotkin
University of Pennsylvania, USA

Biography

Dr. Stanley A. Plotkin is Emeritus Professor of the University of Pennsylvania. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. For seven years he was Medical and Scientific Director of Sanofi Pasteur, based at Marnes-la-Coquette, outside Paris. He is now consultant to vaccine manufacturers and non-profit research organizations.

He is a member of the Institute of Medicine of the National Academy of Sciences and the French Academy of Medicine. His bibliography includes over 700 articles and he has edited a textbook on vaccines, now in its 6th edition. He has been chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics, and Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health. Dr. Plotkin developed the rubella vaccine now in standard use throughout the world, is codeveloper of the pentavalent rotavirus vaccine, and has worked extensively on the development and application of other vaccines including anthrax, oral polio, rabies, varicella, and cytomegalovirus.

 

 
Magdalena Sobieszczyk

OS.03 | 17:13 - 17:36
Insights from HIV Vaccine Efficacy Trials: What We Are Learning from HVTN 505

Magdalena Sobieszczyk
Columbia University, USA

Biography

Dr. Sobieszczyk is an Assistant Professor of Clinical Medicine in the Division of Infectious Diseases at the Columbia University College of Physicians & Surgeons in New York. She is an investigator in the National Institutes of Health sponsored HIV Vaccine Trials Network (HVTN) and is involved in developing and chairing national and international HIV vaccine protocols. Her research focuses on testing, and implementing biomedical strategies to prevent HIV.  She is the protocol co-chair of HVTN 505, a phase 2b protocol evaluating the efficacy and safety of VRC’s DNA prime/rAd5 boost vaccine regimen. Dr. Sobieszczyk is also the protocol chair of HVTN 101, an upcoming phase 1 study evaluating the safety and immunogenicity of DNA/NYVAC/AIDSVAX regimens in South Africa and the United States. Dr. Sobieszczyk completed her training in Internal Medicine and fellowship in Infectious Diseases at Columbia University College of Physicians and Surgeons.

 
 
Anthony Fauci

OS.04 | 17:36 – 18:00
Toward Ending the HIV/AIDS Pandemic: Synergy between Vaccine and Non-Vaccine Interventions

Anthony Fauci
National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA

Biography

Anthony S. Fauci, M.D., is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. Since his appointment as NIAID director in 1984, Dr. Fauci has overseen an extensive research portfolio devoted to preventing, diagnosing, and treating infectious and immune-mediated diseases.  Dr. Fauci also is chief of the NIAID Laboratory of Immunoregulation, where he has made numerous important discoveries related to HIV/AIDS and is one of the most-cited scientists in the field.  Dr. Fauci, a member of the U.S. National Academy of Sciences, has received numerous awards for his scientific accomplishments, including the National Medal of Science, the Mary Woodard Lasker Award for Public Service, and the Presidential Medal of Freedom.  He has been awarded 38 honorary doctoral degrees and is the author, coauthor, or editor of more than 1,200 scientific publications, including several major textbooks.